AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VIR · NASDAQ · Biotechnology

VirBio (VIR)

Develops immune-based medicines for chronic hepatitis delta, solid tumors, and HIV cure research.

$11.21

After hours−0.28 (−2.46%)

At close$11.49(+5.63%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	3	17	56	3	2	12	3	1	0	64	0	239
Cost of revenue	145	106	99	105	195	89	118	98	151	−367	3	0
Gross profit	−142	−90	−42	−102	−193	−76	−115	−96	−151	431	−3	239
	44	49	38	57	38	41	25	22	22	467	130	165
Research & development	145	109	100	105	195	106	119	98	151	88	109	135
	0	0	0	0	0	0	0	0	22	24	23	30
General & administrative	0	0	0	0	0	0	0	0	0	0	0	30
Other expenses	−101	−60	−62	−49	−157	−65	−94	−75	−151	355	−2	0
Operating income	−187	−139	−80	−159	−231	−117	−140	−118	−173	−37	−133	73
	20	18	15	19	18	12	19	8	10	−6	8	7
Interest income	22	21	21	19	18	14	12	11	9	8	7	9
Other non-operating income	−3	−8	−2	−26	−13	−14	−1	0	−10	6	−8	−2
Income before tax	−167	−121	−65	−140	−214	−105	−121	−111	−163	−43	−126	80
Income tax expense	−3	−5	0	−2	0	0	0	0	0	0	0	0
Net income from continuing operations	−163	−116	−65	−138	−214	−105	−121	−111	−163	−43	−126	80
Net income	−163	−116	−65	−138	−214	−105	−121	−111	−163	−43	−126	80
EPS, basic	−$1.22	−$0.86	−$0.48	−$1.02	−$1.56	−$0.76	−$0.88	−$0.80	−$1.17	−$0.31	−$0.85	$0.48
EPS, diluted	−$1.22	−$0.86	−$0.48	−$1.02	−$1.56	−$0.76	−$0.88	−$0.80	−$1.17	−$0.31	−$0.85	$0.47
Weighted average shares, basic	134	135	135	136	137	137	137	138	139	139	147	168
Weighted average shares, diluted	134	135	135	136	137	137	137	138	139	139	147	169
EBITDA	−179	−126	−74	−128	−216	−100	−136	−116	−160	−40	−123	78
Depreciation & amortization	5	4	5	4	3	3	3	3	3	3	3	3
EBIT	−183	−131	−78	−132	−219	−103	−139	−119	−163	−43	−126	76